Posts

The benefits of obesity drugs such as Novo Nordisk’s Wegovy on healthcare systems in countries such as the United States are so significant that the expected entry of rival drugs will not hurt its margins, CEO Lars Jorgensen told Reuters on Tuesday.

Eli Lilly and Co. said on Thursday the U.S. Food and Drug Administration (FDA) had agreed to a quick review of its diabetes drug Mounjaro to treat obesity, months after a study showed it helped people lose more than 20% of their weight.

Nemaura and EVERSANA will work together to develop the optimal launch strategy for large-scale adoption of the diabetes management program, including franchising and direct sales to self-insured corporate clients and healthcare insurers.

On Friday, Merck announced positive results on its patent infringement case against Viatris, while Amgen faces political headwinds from the White House.

A U.S. panel tasked with weighing the pros and cons of regular diabetes screening for children and adolescents found a lack of evidence for the testing, even as the proportion of U.S. youths with type 2 diabetes has doubled since 2001.

On Monday, Bayer revealed data from a Phase III trial of Kerendia (finerenone), showing the drug’s potential to reduce the risk of all-cause and cardiovascular mortality in type 2 

Novo Nordisk shared that its clinical trial of CagriSema, a combination injection for overweight people with type II diabetes, resulted in a 15.6% body weight reduction compared to the drugs dosed individually.

​​​​​​​The FDA will still allow continued distribution of sitagliptin containing NTTP with an acceptable intake limit of 37 ng per day and up to 246.7 ng per day.

A patent cliff is looming once again for the biopharma industry, putting some $236 billion in pharmaceutical sales at risk between now and 2030. For context, the top 10 biopharmas in 2021 generated total global sales of $512 billion. In the next eight years, more than 190 drugs will go off-patent for these companies. Of those, 69 are blockbuster drugs.